
The South Korean government wants to develop a blockchain registry to help analyze, anonymize and store clinical data for diabetes.
Blockchain startup Sendsquare has been selected by the government to develop a proof-of-concept project for the nation, which has around 3.6 million people with diabetes, the company announced on Friday.
The startup will team with clinical experts and practitioners from Seoulâs KyungHee University Medical Center to begin analyzing nine yearsâ worth of diabetes clinical data previously collected by the center.
Related: Binance-Backed Blockchain Auditing Firm Partners With Hdac to Track Internet-of-Things Devices
âStoring and collaborating work across a large volume of data using centralized services has proven unwieldy and subject to issues of data loss, duplication and manipulation,â according to KyungHee Medical Centerâs Professor Suk Chon.
Sendsquareâs blockchain âcan help us to solve data storage problems, and in the long term help diabetes sufferers nationally,â the professor said in a press statement.
The project will take an estimated six months to complete, with the initial objective to analyze the data working to anonymize it before finally implementing the data onto a registry which will be recorded on the FLETA blockchain platform.
See also: South Korean Central Bank Accelerates Digital Currency Pilot to Keep Up With Other Nations
Related: Base Layer Wars Heat Up With Another $12M Committed to AVA Labsâ Avalanche Blockchain
After the blockchain application has been developed, Sendsquare will seek independent verification from Koreaâs Telecommunications Technology Association (TTA).
Sendsquare is a blockchain startup responsible for the development of the South Korea-based FLETA blockchain which was previously charged with building a proof-of-concept network for the nationâs healthcare system.
Related Stories
- Cambodia Plots a Dollar-Free Future With Blockchain-Based Payments: White Paper
- South Korean Soccer League Tokenizes Players for Fantasy Football Game
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.